MX357021B - Derivados de imidazo[1,2-b]piridazina como inhibidores de cinasa. - Google Patents

Derivados de imidazo[1,2-b]piridazina como inhibidores de cinasa.

Info

Publication number
MX357021B
MX357021B MX2014014803A MX2014014803A MX357021B MX 357021 B MX357021 B MX 357021B MX 2014014803 A MX2014014803 A MX 2014014803A MX 2014014803 A MX2014014803 A MX 2014014803A MX 357021 B MX357021 B MX 357021B
Authority
MX
Mexico
Prior art keywords
imidazo
kinase inhibitor
pyridazine derivative
acceptable salt
pharmacologically acceptable
Prior art date
Application number
MX2014014803A
Other languages
English (en)
Other versions
MX2014014803A (es
Inventor
Takeda Yasuyuki
Yoshikawa Kenji
Kagoshima Yoshiko
Yamamoto Yuko
Tanaka Ryoichi
Tominaga Yuichi
Kiga Masaki
Hamada Yoshito
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2014014803A publication Critical patent/MX2014014803A/es
Publication of MX357021B publication Critical patent/MX357021B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

La presente invención está destinada a proporcionar un compuesto o una sal farmacológicamente aceptable del mismo el cual es útil en el tratamiento de un tumor a través del efecto inhibidor de la actividad de la enzima ROS1 cinasa y el efecto inhibidor de la enzima NTRK cinasa. La presente invención proporciona un compuesto que tiene estructura imidazo [1,2-b] piridazina representado por la fórmula general (I) o una sal farmacológicamente aceptable del mismo, y una composición farmacéutica que comprende al compuesto. En la fórmula, R1, G, T, Y1, Y2, Y3 e Y4 son como se definen en la presente.
MX2014014803A 2012-06-04 2013-06-03 Derivados de imidazo[1,2-b]piridazina como inhibidores de cinasa. MX357021B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[１，２－ｂ]ピリダジン誘導体

Publications (2)

Publication Number Publication Date
MX2014014803A MX2014014803A (es) 2015-02-12
MX357021B true MX357021B (es) 2018-06-25

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014803A MX357021B (es) 2012-06-04 2013-06-03 Derivados de imidazo[1,2-b]piridazina como inhibidores de cinasa.

Country Status (32)

Country Link
US (2) US9187489B2 (es)
EP (1) EP2857404B1 (es)
JP (1) JP5814467B2 (es)
KR (1) KR101781255B1 (es)
CN (1) CN104520300B (es)
AU (1) AU2013272701B2 (es)
BR (1) BR112014029851B1 (es)
CA (1) CA2874819C (es)
CO (1) CO7160119A2 (es)
CY (1) CY1119607T1 (es)
DK (1) DK2857404T3 (es)
ES (1) ES2648228T3 (es)
HK (1) HK1207374A1 (es)
HR (1) HRP20171724T1 (es)
HU (1) HUE037221T2 (es)
IL (1) IL236075A (es)
IN (1) IN2014MN02497A (es)
LT (1) LT2857404T (es)
MX (1) MX357021B (es)
MY (1) MY170326A (es)
NO (1) NO2857404T3 (es)
NZ (1) NZ702574A (es)
PH (1) PH12014502721B1 (es)
PL (1) PL2857404T3 (es)
PT (1) PT2857404T (es)
RS (1) RS56625B1 (es)
RU (1) RU2635917C2 (es)
SG (1) SG11201408052WA (es)
SI (1) SI2857404T1 (es)
TW (1) TWI585088B (es)
WO (1) WO2013183578A1 (es)
ZA (1) ZA201408843B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738026C (en) 2008-09-22 2017-01-24 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
DK3106463T6 (da) 2008-10-22 2020-02-24 Array Biopharma Inc Pyrazolo[1,5-]pyrimidinforbindelse som trk-kinasehæmmer
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
HUE035337T2 (en) 2010-05-20 2018-05-02 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
KR20150015501A (ko) 2012-05-30 2015-02-10 니뽄 신야쿠 가부시키가이샤 방향족 복소환 유도체 및 의약
EA032255B1 (ru) 2014-03-27 2019-04-30 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРАЗИНА И ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРО-4H-ПИРАЗОЛО[1,5-a][1,4]ДИАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Ros1
EA031639B1 (ru) * 2014-03-27 2019-01-31 Янссен Фармацевтика Нв ЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-а]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ И 2,3-ДИГИДРО-1H-ИМИДАЗО[1,2-b]ПИРАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ROS1
JP6696908B2 (ja) * 2014-04-25 2020-05-20 エグゼリクシス， インコーポレイテッド 肺腺癌の治療方法
DK3699181T3 (da) 2014-11-16 2023-03-20 Array Biopharma Inc Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
EA201792679A1 (ru) 2015-06-01 2018-06-29 Локсо Онколоджи, Инк. Способы диагностики и лечения злокачественной опухоли
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
CA3014432A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2018000138A1 (en) 2015-10-26 2019-10-04 Array Biopharma Inc Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
MA44612A (fr) 2016-04-04 2019-02-13 Loxo Oncology Inc Méthodes de traitement de cancers pédiatriques
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
EP3597648B1 (en) * 2017-03-14 2023-06-07 Daiichi Sankyo Company, Limited METHOD FOR PRODUCING 3, 6-DISUBSTITUTED IMIDAZO[1, 2-b]PYRIDAZINE DERIVATIVE
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
WO2019107671A1 (ko) * 2017-11-29 2019-06-06 서울대학교 산학협력단 항-ros1 항체 및 그의 용도
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
US20220185815A1 (en) * 2019-03-06 2022-06-16 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
SG11202112381VA (en) * 2019-05-08 2021-12-30 Tyk Medicines Inc Compound used as kinase inhibitor and application thereof
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202200589A (zh) * 2020-05-28 2022-01-01 瑞士商諾華公司 Ｍｌｌ１抑制劑及抗癌劑
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
WO2023272701A1 (en) * 2021-07-01 2023-01-05 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
WO2023220967A1 (en) * 2022-05-18 2023-11-23 Anheart Therapeutics (Hangzhou) Co., Ltd. Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds
CN114989176A (zh) * 2022-07-08 2022-09-02 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115A (zh) * 2022-08-25 2022-10-18 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
JP2004508366A (ja) 2000-09-01 2004-03-18 グラクソ　グループ　リミテッド オキシインドール誘導体
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005103010A2 (en) 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
WO2006070943A1 (ja) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
PL1846394T3 (pl) 2005-02-04 2012-04-30 Astrazeneca Ab Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
AU2006215394B2 (en) 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
EP1912987A1 (en) * 2005-08-01 2008-04-23 F. Hoffmann-Roche AG Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
KR101546493B1 (ko) * 2006-11-06 2015-08-21 톨레로 파마수티컬스, 인크. 이미다조[1,2-ｂ]피리다진 및 피라졸로[1,5-ａ]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ［１，２－ｂ］ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
US8507488B2 (en) 2008-05-13 2013-08-13 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
CA2738026C (en) * 2008-09-22 2017-01-24 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
IL236075A (en) 2017-10-31
BR112014029851B1 (pt) 2023-01-03
US9187489B2 (en) 2015-11-17
SI2857404T1 (sl) 2017-11-30
JPWO2013183578A1 (ja) 2016-01-28
EP2857404A4 (en) 2016-01-20
PL2857404T3 (pl) 2018-04-30
AU2013272701A1 (en) 2015-01-15
BR112014029851A2 (pt) 2017-06-27
JP5814467B2 (ja) 2015-11-17
IL236075A0 (en) 2015-02-01
PT2857404T (pt) 2017-11-23
AU2013272701B2 (en) 2017-12-21
KR20150014942A (ko) 2015-02-09
TWI585088B (zh) 2017-06-01
SG11201408052WA (en) 2015-01-29
MX2014014803A (es) 2015-02-12
ES2648228T3 (es) 2017-12-29
PH12014502721A1 (en) 2015-02-02
CA2874819A1 (en) 2013-12-12
EP2857404B1 (en) 2017-08-23
KR101781255B1 (ko) 2017-09-22
DK2857404T3 (en) 2017-12-04
US20160046639A1 (en) 2016-02-18
MY170326A (en) 2019-07-17
EP2857404A1 (en) 2015-04-08
LT2857404T (lt) 2017-11-10
RU2014153627A (ru) 2016-08-10
AU2013272701A2 (en) 2015-01-22
ZA201408843B (en) 2016-01-27
US9751887B2 (en) 2017-09-05
PH12014502721B1 (en) 2015-02-02
CN104520300A (zh) 2015-04-15
CA2874819C (en) 2017-06-20
RS56625B1 (sr) 2018-03-30
HK1207374A1 (en) 2016-01-29
RU2635917C2 (ru) 2017-11-17
TW201400486A (zh) 2014-01-01
HUE037221T2 (hu) 2018-08-28
HRP20171724T1 (hr) 2018-01-12
NO2857404T3 (es) 2018-01-20
CO7160119A2 (es) 2015-01-15
US20150051190A1 (en) 2015-02-19
CY1119607T1 (el) 2018-04-04
NZ702574A (en) 2016-07-29
IN2014MN02497A (es) 2015-07-17
WO2013183578A1 (ja) 2013-12-12
CN104520300B (zh) 2016-12-21

Similar Documents

Publication Publication Date Title
PH12014502721A1 (en) IMIDAZO[1,2-b] PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
TN2014000042A1 (en) Cyclopropaneamine compound
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX340402B (es) Inhibidores triciclicos de cinasas.
MX336381B (es) Boronatos como inhibidores de arginasa.
MA34064B1 (fr) Compose heterocyclique
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MD4556B1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MY195209A (en) Partially Saturated Nitrogen-Containing Heterocyclic Compound
EA024194B8 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
TN2012000092A1 (en) Therapeutic agent for mood disorders
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
MX2013007937A (es) Nuevo derivado de indol o indazol o sal del mismo.
PH12015501146A1 (en) Hydantoin derivative
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel

Legal Events

Date Code Title Description
FG Grant or registration